Scarica l'app Stockscreener
0.7873
3.24%
-0.0264
Dopo l'orario di chiusura:
.78
-0.0073
-0.93%
Precedente Chiudi:
$0.8137
Aprire:
$0.788925
Volume 24 ore:
65,271
Relative Volume:
0.08
Capitalizzazione di mercato:
$32.37M
Reddito:
$1.88M
Utile/perdita netta:
$-8.48M
Rapporto P/E:
-4.1855
EPS:
-0.1881
Flusso di cassa netto:
$-19.13M
1 W Prestazione:
+1.30%
1M Prestazione:
+28.85%
6M Prestazione:
-54.36%
1 anno Prestazione:
-54.49%
Intervallo 1D:
$0.7842
$0.8494
Intervallo di 1 settimana:
$0.57
$1.14
Portata 52W:
$0.5657
$2.44
Beyondspring Inc Stock (BYSI) Company Profile
Nome
Beyondspring Inc
Settore
Industria
Telefono
646-528-4184
Indirizzo
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
0.7873 | 31.96M | 1.88M | -8.48M | -19.13M | -0.1881 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-02 | Downgrade | Jefferies | Buy → Hold |
| 2021-12-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | Iniziato | BofA Securities | Buy |
| 2020-12-29 | Iniziato | Evercore ISI | Outperform |
| 2020-02-07 | Iniziato | Jefferies | Buy |
| 2020-01-10 | Iniziato | Nomura | Buy |
| 2019-12-03 | Iniziato | William Blair | Outperform |
| 2019-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-30 | Downgrade | Maxim Group | Buy → Hold |
| 2018-10-25 | Reiterato | Maxim Group | Buy |
Mostra tutto
Beyondspring Inc Borsa (BYSI) Ultime notizie
BeyondSpring Inc. Announces FDA Fast Track Designation For Plinabulin And Docetaxel In Post-ICI Non-Squamous NSCLC - marketscreener.com
BYSI Forecast — Price Target — Prediction for 2027 - TradingView
'Beyond Spring and Fall': Apple Prepares Organization Restructure for Accelerating Product Launches - TradingView
BeyondSpring Receives FDA Fast Track for Plinabulin - grafa.com
Form 8K BeyondSpring Inc For: 29 September By Investing.com - Investing.com Nigeria
BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances - Yahoo Finance
Form 424B5 BeyondSpring Inc For: 29 September By Investing.com - Investing.com Nigeria
BeyondSpring launches ATM program to bolster financing - TipRanks
FDA grants fast track status to BeyondSpring’s lung cancer drug - Investing.com
Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares - TradingView
About 221 patients are expected to enroll in China, with an investor helping fund the lung cancer trial. - Stock Titan
BeyondSpring Announces FDA Fast Track Designation for - GlobeNewswire
Beyondspring Inc (BYSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Premarket movers: GRML and BTTC lead gainers, IMCC and DLXY lead losers - ChartMill
Beyondspring Stock Price Forecast. Should You Buy BYSI? - StockInvest.us
BeyondSpring Faces Nasdaq Noncompliance Over Minimum Bid Price - TipRanks
BeyondSpring Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
BeyondSpring (BYSI): Plinabulin Advances While the Balance Sheet Reaches a Critical Threshold - news.alphastreet.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
BeyondSpring (NASDAQ: BYSI) Announces 2026 Annual General Meeting with Virtual Access - kalkinemedia.com
BeyondSpring Inc. SEC Filing (Sep 3, 2026) - stocktitan.net
BeyondSpring (BYSI) plans Oct. 13 vote on 2026 auditor - stocktitan.net
Intelligent Bio Solutions Raises Up to $15M in Private Placement - Minichart
BeyondSpring (BYSI) EPS and Revenue: The Company Lists Its Latest Available Figures for This Review; Stock Move: The Stock Records a Flat Reaction in the Current UpdateAnalyst Coverage Count - vinanet.vn
BeyondSpring (BYSI) Results Versus Estimates: Available Data Shows the Latest Reported Performance in Latest Trading; Market Reaction: Shares Close 0.28% Lower in the Current UpdatePositive Surprise Momentum - vinanet.vn
BeyondSpring (BYSI) Range: Adds 4.89% to Close at $0.75 in the Current Update; Market Levels: the Supplied Trading Band Runs From $0.71 to $0.79 in the Latest SessionSMA Signal - vinanet.vn
BeyondSpring Inc. (BYSI) Reports Q2 Loss of $0.02 - StreetInsider
BeyondSpring (BYSI) Q2 Results Highlight Challenges Amid High Price-to-Sales Valuation - GuruFocus
BeyondSpring (BYSI) Slides 15.78% to $0.84 as Key Support NearsValue Area High - vinanet.vn
BYSI Q1 2026 Earnings: Net Loss Per Share of $0.05 Reported as Shares Slide 15.78%Investor Earnings Call - vinanet.vn
BeyondSpring (BYSI) Plunges 15.78% to $0.84 as Key Support at $0.80 Comes into FocusMax Pain Level - siam.in
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
BeyondSpring Cash Drops to $6.4M, Escalating Going-Concern Risk - minichart.com.sg
BeyondSpring Cash Drops to $6.5M as DUBLIN-4 Trial Funding Looms - Minichart
BeyondSpring Q2 loss narrows to $849k; EPS improves to $(0.02) - scanx.trade
BeyondSpring Inc. (BYSI) founders disclose 5.29M shares each in 13G/A - Stock Titan
BYSI: Net loss increased to $5.7M in Q2 2026, with urgent need for new funding amid ongoing R&D - TradingView
BeyondSpring (BYSI) posts deeper H1 2026 loss and flags going concern risk - Stock Titan
BeyondSpring Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BeyondSpring Posts $5.7 Million Second-Quarter Net Loss - Quiver Quantitative
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BYSI Q1 2026 Earnings: Loss Per Share of $0.05 Reported as Shares Rise 7.01%Earnings Call Transcript - vinanet.vn
Beyondspring Inc (BYSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vascular Disrupting Agents Market - Future Market Insights
Beyondspring Inc (BYSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Pre-Revenue Biotech Reports Narrowed Loss Amid Pipeline ProgressShort-Term Outlook - dars.gov.et
BYSI Q1 2026 Earnings: Narrowed Loss Reflects Continued Clinical ProgressTax Rate Impact - dars.gov.et
Beyondspring Inc (BYSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BYSI|Beyondspring Inc|Price:0.720|Chg%:-0.002 - TradingKey
Beyondspring Inc (BYSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beyondspring Inc (BYSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beyondspring Inc Azioni (BYSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Beyondspring Inc Azioni (BYSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sci | 10% Owner |
Oct 17 '25 |
Sale |
1.76 |
45,513 |
80,103 |
1,518,893 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 13 '25 |
Sale |
1.70 |
107,361 |
182,514 |
1,696,659 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 14 '25 |
Sale |
1.65 |
28,495 |
47,017 |
1,668,164 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 15 '25 |
Sale |
1.65 |
17,960 |
29,634 |
1,650,204 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 08 '25 |
Sale |
1.77 |
7,507 |
13,287 |
1,810,389 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 09 '25 |
Sale |
1.81 |
3,979 |
7,202 |
1,806,410 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 10 '25 |
Sale |
1.77 |
2,390 |
4,230 |
1,804,020 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 06 '25 |
Sale |
1.78 |
17,500 |
31,150 |
1,819,996 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 07 '25 |
Sale |
1.79 |
2,100 |
3,759 |
1,817,896 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 03 '25 |
Sale |
1.76 |
600 |
1,056 |
1,837,496 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):